| Theme |
Early detection and prevention for cancer of dialysis patients |
| Title |
Erythropoiesis stimulating agents for managing anemia in patients with cancer |
| Author |
Noritomo Itami |
Kidney Center, Nikko Memorial Hospital |
| Author |
Teiryo Maeda |
Maeda Institute of Renal Research |
| [ Summary ] |
Approximately 90 % of the erythropoiesis stimulating agents (ESA) used in treatment for renal anemia in hemodialysis patients have not been approved in Japan. However, in Europe and America they are used for cancer patients in chemotherapy related to chemotherapy induced anemia (CIA). It has been reported in a meta-analysis study that in recent years, patients who had used ESA for CIA had poorer prognoses than patients who did not. With the advancing age of the hemodialysis population, there is an increased likelihood of encountering hemodialysis patients with a history of cancer or who are developing cancer. When treating anemia in these patients, careful treatment through monitoring anemic symptoms, is required to prevent the quantity of ESA from becoming excessive. |